Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing
18/12/2025 23:28
Dec 18 (Reuters) - Cassava Sciences Inc SAVA.O: CASSAVA SCIENCES INC - ON DEC 15, FDA PLACES FULL CLINICAL HOLD ON CASSAVA'S TRIAL - SEC FILING CASSAVA SCIENCES: NOT EXPECTED TO INITIATE PROOF-OF-CONCEPT CLINICAL TRIAL FOR SIMUFILAM IN TSC-RELATED EPILEPSY IN H1 2026 AS PREVIOUSLY DISCLOSED Source text: [ID:n0001437749-25-038313] Further company coverage: SAVA.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing